Ratings by BMO Capital (Evan Seigerman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/10/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2026 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/5/2026 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2026 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/26/2026 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/14/2026 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/14/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/23/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/18/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/20/2025 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/10/2025 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/5/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2025 | Replimune Group | REPL | Upgrade | Market Perform (Underperform) |
10.25 (8.07) |
-21.27% | Details | |
| 10/14/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/18/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/10/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/18/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/7/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/30/2025 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 7/29/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/23/2025 | Replimune Group | REPL | Downgrade | Underperform (Outperform) |
12.32 (10.25) |
-16.8% | Details | |
| 7/22/2025 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2025 | Neurogene | NGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 5/19/2025 | Neurogene | NGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/14/2025 | Novo Nordisk | NVO | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/17/2025 | Novo Nordisk | NVO | Downgrade | Market Perform (Outperform) |
62.88 (38.58) |
-38.65% | Details | |
| 3/25/2025 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2025 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/24/2025 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/21/2025 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2024 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2024 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 10/30/2024 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 10/21/2024 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2024 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2024 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 7/8/2024 | Morphic Therapeutic | MORF | Downgrade | Market Perform (Outperform) |
31.84 (56.99) |
78.99% | Details | |
| 7/2/2024 | Incyte | INCY | Downgrade | Underperform (Market Perform) |
60.62 (95.94) |
58.26% | Details | |
| 6/26/2024 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2024 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2024 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/17/2024 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2024 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/2/2023 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2023 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2023 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/25/2023 | Morphic Therapeutic | MORF | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2023 | Structure Therapeutics | GPCR | New Coverage | Outperform (N/A) |
24.30 (57.73) |
137.57% | Details | |
| 12/12/2022 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2022 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details |
